Last updated: April 25, 2026
Who Supplies Natesto (Testosterone) in the US Supply Chain?
What is Natesto and who makes it?
Natesto is a prescription testosterone product in the US. It is marketed by Clarus Therapeutics and was commercially developed and brought to market by Endo Pharmaceuticals historically. The product is a nasal testosterone formulation approved for testosterone replacement therapy in adult men with hypogonadism.
Commercial label holder (US): Clarus Therapeutics.
Original developer / company associated with launch: Endo Pharmaceuticals.
Who are the known manufacturing and development parties?
For Natesto, the public record most reliably identifies the label holder and the originating corporate developer. Public, non-confidential information about specific third-party API makers and specific finished-dose contract manufacturing organizations (CMOs) is not consistently disclosed in a way that can be stated accurately for Natesto without risking misassignment of suppliers.
The actionable, defensible “supplier” list for decision-making therefore centers on parties that are consistently identifiable from regulatory and market records: the marketing authorization holder and the originating developer tied to the initial product commercialization.
Supplier map (actionable for diligence)
| Supplier function |
Identified party |
Role in Natesto commercialization |
| US label holder / commercialization |
Clarus Therapeutics |
Holds product marketing rights in the US and manages commercial supply responsibility under its regulatory obligations. |
| Originating developer / launch company |
Endo Pharmaceuticals |
Associated with development and original commercialization of Natesto historically. |
What does this mean for procurement and risk screening?
- Label-holder managed supply chain: In practice, the label holder typically controls release strategy, specifications, and quality oversight even when production is done by contracted manufacturers. This is the supplier entry point for quality agreements, CoA flow-downs, change notifications, and audit schedules.
- Vendor identification for API and CMO requires direct dossier traceability: For Natesto, supplier-level API/CMO identity is not uniformly published in accessible summaries. The correct method for procurement diligence is to trace supplier names through regulatory submissions and inspections tied to the specific marketed strength and dosage form.
Key Takeaways
- Natesto’s US commercialization is tied to Clarus Therapeutics as the marketing party.
- The product’s development and original commercialization are tied to Endo Pharmaceuticals historically.
- Publicly citable sources support label-holder and originating developer identification, while specific API/CMO suppliers are not consistently named in open materials in a way that can be stated without misattribution risk.
FAQs
1) Who can a purchaser contact first to obtain Natesto supplier documentation?
Clarus Therapeutics, as the US marketing and label party for Natesto.
2) Who originally developed Natesto?
Endo Pharmaceuticals is the originating developer associated with Natesto’s historical launch and commercialization.
3) Are API and CMO suppliers publicly listed for Natesto?
Not consistently in publicly accessible sources. Procurement diligence typically requires traceability through regulatory submissions and quality agreements with the label holder.
4) Does Natesto have multiple manufacturers across sites?
Commercial product supply can involve multiple production sites over time, but site-level manufacturing identities must be validated through dossier traceability and current quality documentation from the label holder.
5) What supplier documents are typically required for a Natesto sourcing decision?
CoAs, GMP compliance evidence, change control notifications, and quality agreement terms via the label holder.
References
[1] FDA. Drug Approvals and Databases: Natesto (testosterone nasal gel). U.S. Food and Drug Administration. https://www.accessdata.fda.gov
[2] Clarus Therapeutics. Company and product information for Natesto. Clarus Therapeutics (investor and product materials). https://www.clarusrx.com
[3] Endo Pharmaceuticals. Historical corporate information related to Natesto commercialization. Endo Pharmaceuticals (archived and corporate materials). https://www.endo.com
